Rybelsus® (semaglutide) tablets is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.
Rybelsus® (semaglutide) tablets
Choose an area of interest below to access videos featuring specific information about Rybelsus®.
Pharmacology
-
Rybelsus® Mechanism of Action
This video discusses the mechanism of action of Rybelsus®.
-
Rybelsus® Mechanism of Absorption
This video discusses the mechanism of absorption of Rybelsus®.
-
Pharmacokinetic, Pharmacodynamic (PK/PD) & Dosing Considerations for Rybelsus®
This video describes PK/PD considerations that can impact the dosing of Rybelsus®.
-
Drug Interactions with Rybelsus®
This video reviews potential drug-drug interactions with Rybelsus®.
Glycemic Control Trials
-
Rybelsus® vs. Placebo in Drug-Naïve Adults (PIONEER 1 Study)
This video discusses the trial-design and outcomes of the PIONEER 1 study. PIONEER 1 was a 26-week, phase 3a, randomized, double-blind, parallel group, multinational trial in 703 adult patients with type 2 diabetes managed with diet and exercise alone.
-
Rybelsus® vs. Placebo as Add-on to Insulin (PIONEER 8 Study)
This video discusses the trial-design and outcomes of the PIONEER 8 study. PIONEER 8 was a 52-week, phase 3a, randomized, double-blind, parallel-group, multinational trial enrolling 731 adults with type 2 diabetes.
-
Rybelsus® 14 mg vs. Empagliflozin 25 mg (PIONEER 2 Study)
This video discusses the trial-design and outcomes of the PIONEER 2 study. PIONEER 2 was a 52-week, phase 3a, randomized, open-label, multinational trial enrolling 822 adults with type 2 diabetes.
-
Rybelsus® vs. Sitagliptin 100 mg (PIONEER 3 Study)
This video discusses the trial-design and outcomes of the PIONEER 3 study. PIONEER 3 was a 78-week, phase 3a, randomized, double-blind, double-dummy, multinational trial enrolling 1864 adults with type 2 diabetes.
-
Rybelsus® 14 mg vs. Victoza® 1.8 mg vs. Placebo (PIONEER 4 Study)
This video discusses the trial-design and outcomes of the PIONEER 4 study. PIONEER 4 was a 52-week, phase 3a, randomized, double-blind, double-dummy, active- and placebo-controlled, multinational trial in 711 adults with type 2 diabetes.
-
Flexible Dosing of Rybelsus® vs. Sitagliptin 100 mg (PIONEER 7 Study)
This video discusses the trial-design and outcomes of the PIONEER 7 study. PIONEER 7 was a 52-week, phase 3a, randomized, open-label, multinational trial with a 52-week extension enrolling 504 adults with type 2 diabetes.
Specific Population Studies
-
Rybelsus® 14 mg vs. Placebo in Adults with Moderate Renal Impairment (PIONEER 5 Study)
This video discusses the trial-design and outcomes of the PIONEER 5 study. PIONEER 5 was a 26-week, phase 3a, randomized, double-blind, multinational trial enrolling 324 adults with type 2 diabetes and moderate renal impairment.
-
Cardiovascular Safety of Rybelsus® vs. Placebo (PIONEER 6 Study)
This video discusses the trial-design and outcomes of the PIONEER 6 study. PIONEER 6 was a phase 3a, randomized, double-blind, multinational trial that enrolled 3183 adult patients (age ≥50 years) with type 2 diabetes. Eligible patients were at least 50 years of age with established cardiovascular (CV) disease or chronic kidney disease, or patients were at least 60 years of age with at least one CV risk factor.
The search will retrieve any scientific documents from the medical information database where the search terms match either the title or content of the document. The response(s) are not intended to offer recommendations for administering Novo Nordisk products in a manner inconsistent with approved labeling. To access the Prescribing Information for Novo Nordisk products, please click here.
Search for Letters
Find documents for this product by entering your search terms in the box below.
Have a Question?
Request information directly from the Novo Nordisk
Medical Information department.
Have a Question?
All fields required.